| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 27, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Jan. 27, 2012-- Medtronic, Inc. (NYSE: MDT) today announced that it has entered into an exclusive distribution agreement with Miami Instruments, LLC – a company...
-
Jan 24, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Jan. 24, 2012-- Medtronic, Inc. (NYSE: MDT) today announced the first patient was enrolled in the FIRE AND ICE clinical trial, which is a prospective, randomized,...
-
Jan 24, 2012CoreValve U.S. Trial to Continue Enrolling Patients in High Risk Study, and Will Maintain Therapy Access to Extreme Risk Patients via Continued Access Phase of Trial
MINNEAPOLIS, Jan 24, 2012 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) today announced it has completed patient enrollment in the extreme risk study in its CoreValve U.S. Pivotal Trial. The...
-
Jan 23, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Jan. 23, 2012-- Medtronic, Inc. (NYSE:MDT) announced today that it has received 510(k) clearance from the Food and Drug Administration (FDA) for the Aquamantys® SBS...
-
Jan 17, 2012Enhanced Medical Device to Repair Abdominal Aortic Aneurysms Without Open Surgery Expands Physicians’ Options for Treating ‘Silent Killer’
MINNEAPOLIS--(BUSINESS WIRE)--Jan. 17, 2012-- Medtronic Inc. (NYSE: MDT) today announced the CE (Conformité Européenne) mark and international launch of the Endurant®II AAA Stent Graft System,...
-
Jan 17, 2012Enhanced Medical Device to Repair Abdominal Aortic Aneurysms Without Open Surgery Expands Physicians' Options for Treating 'Silent Killer'
MINNEAPOLIS, Jan 17, 2012 (BUSINESS WIRE) --Medtronic Inc. (NYSE: MDT) today announced the CE (Conformité Européenne) mark and international launch of the Endurant(R) II AAA Stent Graft System,...
-
Jan 4, 2012mySentry Allows Caregivers to See Real-Time Insulin Pump Information and Glucose Trends from Another Room
MINNEAPOLIS--(BUSINESS WIRE)--Jan. 4, 2012-- Today, Medtronic, Inc. (NYSE:MDT) announced U.S. Food and Drug Administration (FDA) approval and U.S. market launch of the first-of-its-kind...
-
Dec 23, 2011
MINNEAPOLIS--(BUSINESS WIRE)--Dec. 23, 2011-- Medtronic, Inc. (NYSE: MDT), the world’s leading medical technology company, today announced it will participate in the 30th Annual JP Morgan...
-
Dec 20, 2011
MINNEAPOLIS--(BUSINESS WIRE)--Dec. 22, 2011-- Medtronic, Inc. (NYSE: MDT), the world’s leading medical technology company, today announced it will participate in the Goldman Sachs Healthcare...
-
Dec 12, 2011
MINNEAPOLIS--(BUSINESS WIRE)--Dec. 12, 2011-- Medtronic, Inc. (NYSE: MDT) today announced that the Company has reached a settlement agreement with the United States Department of Justice (DOJ)...
-
Dec 10, 2011
MINNEAPOLIS, Nov 10, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the second quarter of its fiscal year 2012 on Tuesday, November 22,...
-
Dec 9, 2011Neurostimulator with Innovative Motion Sensor Technology Was Recently Approved by the FDA for the Management of Chronic Pain
MINNEAPOLIS--(BUSINESS WIRE)--Dec. 9, 2011-- Clinical trial data presented at the 15th Annual Meeting of the North American Neuromodulation Society demonstrate the AdaptiveStim™ with...
-
Dec 8, 2011
MINNEAPOLIS, Dec 08, 2011 (BUSINESS WIRE) -- The board of directors of Medtronic, Inc. (NYSE:MDT) today approved a cash dividend of $0.2425 per share of the Company's common stock. The dividend is...
-
Dec 7, 2011Medtronic CRT-D Devices Demonstrate Survival Benefits for Mildly Symptomatic Heart Failure Patients in Two Pivotal Clinical Trials
MINNEAPOLIS--(BUSINESS WIRE)--Dec. 7, 2011-- Medtronic, Inc. (NYSE: MDT) today announced that the U.S. Food and Drug Administration’s (FDA) Circulatory Systems Devices Advisory Panel determined...
-
Nov 21, 2011
MINNEAPOLIS--(BUSINESS WIRE)--Nov. 21, 2011-- Medtronic, Inc. (NYSE: MDT), the world’s leading medical technology company, today announced it will participate in the Piper Jaffray Healthcare...
-
Nov 20, 2011Revenue of $4.1 Billion Grew 3% on a Constant Currency Basis, 6% as Reported
MINNEAPOLIS--(BUSINESS WIRE)--Nov. 22, 2011-- Medtronic, Inc. (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2012, which ended October 28, 2011. The company...
-
Nov 20, 2011iPro®2 Simplifies Professional CGM for Improved Diabetes Therapy Management
MINNEAPOLIS--(BUSINESS WIRE)--Nov. 22, 2011-- Medtronic, Inc. (NYSE:MDT) today announced the Food and Drug Administration (FDA) approval of iPro®2, a next generation Professional continuous...
-
Nov 17, 2011
MINNEAPOLIS & BOSTON--(BUSINESS WIRE)--Nov. 17, 2011-- Medtronic, Inc. (NYSE:MDT) and Bain Capital, a leading global private investment firm, today announced they have entered into a definitive...
-
Nov 17, 2011Neurostimulator Uses Innovative Motion Sensor Technology to Provide Patient Comfort and Convenience
MINNEAPOLIS--(BUSINESS WIRE)--Nov. 17, 2011-- Medtronic, Inc. (NYSE: MDT) today announced the U.S. Food & Drug Administration (FDA) approval of its AdaptiveStim™ with RestoreSensor™...
-
Nov 10, 2011Campaign Empowers People With a Slow Heartbeat to Learn About Treatment Options and How to Have an Informed Discussion With Their Doctor
Famed dancer, actress, and director Debbie Allen has teamed up with Medtronic, Inc. (NYSE: MDT) today to kick off "Join the Pace Makers," a national campaign designed to empower people with a...
-
Nov 9, 2011
MINNEAPOLIS, Nov 09, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today reported results of an retrospective study available online and in an upcoming print edition of the Journal of Spinal...
-
Nov 9, 2011Study Will Evaluate Accuracy of Latest Innovation to Help People with Diabetes Improve Glucose Control
MINNEAPOLIS, Nov 09, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced a new United States investigational device exemption study to evaluate the accuracy of six-day use in...
-
Nov 8, 2011Pooled Data Analyses to Be Presented at TCT 2011 Demonstrate Heart Device's Consistently Positive Performance Across Multiple Clinical Studies
SAN FRANCISCO, Nov 08, 2011 (BUSINESS WIRE) -- Currently under review by the U.S. Food and Drug Administration (FDA), the Resolute(R) drug-eluting stent (DES) from Medtronic, Inc. (NYSE: MDT)...
-
Nov 8, 2011Final Five-Year Follow-up of Randomized ENDEAVOR IV Trial Shows Durable Safety and Efficacy of Endeavor DES, with Comparatively Lower Rates of Cardiac Death/Myocardial Infarction and Very Late Stent Thrombosis
SAN FRANCISCO, Nov 08, 2011 (BUSINESS WIRE) -- New research findings released at TCT 2011 show that the Endeavor(R) zotarolimus-eluting stent (DES) from Medtronic, Inc. (NYSE: MDT) outperformed...
-
Nov 7, 2011New Access Will Expand Treatment Options for Patients with Severe Aortic Stenosis
MINNEAPOLIS, Nov 07, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced it has received CE (Conformité Européenne) Mark for the Medtronic CoreValve(R) System to be delivered...